Skip to main content

Black Diamond Therapeutics, Inc.

For the period ended Jun 30, 2025. Filed Aug 7, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Aug 7, 2025

BDTX$1.60-14.2%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited)

(in thousands, except share and per share data)

Three Months EndedJune 30,Six Months EndedJune 30,
2025202420252024
License revenue$—$—$70,000$—
Operating expenses:
Research and development$9,319$12,556$19,825$26,101
General and administrative4,1019,5749,06516,275
Total operating expenses13,42022,13028,89042,376
Income (loss) from operations(13,420)(22,130)41,110(42,376)
Other income (expense):
Interest income1,1184641,7131,101
Other income (expense)1,7411,7573,1583,141
Total other income (expense), net2,8592,2214,8714,242
Net income (loss)$(10,561)$(19,909)$45,981$(38,134)
Net income (loss) per share - basic$(0.19)$(0.36)$0.81$(0.71)
Net income (loss) per share - diluted$(0.19)$(0.36)$0.80$(0.71)
Weighted average common shares outstanding - basic56,803,45055,155,22056,734,01053,482,034
Weighted average common shares outstanding - diluted56,803,45055,155,22057,474,11853,482,034
Comprehensive income (loss):
Net income (loss)$(10,561)$(19,909)$45,981$(38,134)
Other comprehensive income (loss):
Unrealized gain (loss) on investments, net(6)(20)(49)(88)
Comprehensive income (loss)$(10,567)$(19,929)$45,932$(38,222)
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.